F-D-C Reports Management Change: Editorial Continuity, New Web Ventures
This article was originally published in Pharmaceutical Approvals Monthly
F-D-C Reports President Tim Harrington’s focus will be web-based news services that build on the reputation of editorial quality associated with the publisher of Pharmaceutical Approvals Monthly and "The Pink Sheet."
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class